SERVICES

Nuclera Antibody Services: Rapid Hit Triage & Validation

The missing triage step for AI antibody discovery. Filter out non-binders before high-cost downstream validation—fast, and from just ~$100* per antibody.

Shrink the list. Save resources.

When teams are constrained by capacity, high costs, access to wet labs and fragmented hit validation, our rapid antibody screening service converts large AI-generated panels into decision-grade binding outputs.

Using binary cell-free antibody expression and binding screening, we triage out non-binders early and perform SPR on prioritized candidates, allowing you to reserve expensive downstream validation for only your strongest candidates.

Download Flyer

Talk To An Expert

Key benefits of our rapid Antibody Screening Service

Cost-effective screening

Rapidly convert large AI-generated libraries into experimental data from ~$100* per antibody.

antibody-services-icon-end-to-end-triage

Upstream triage

Eliminate non-binders early without adding CapEx or headcount.

Decision-grade data

Automated workflows delivering consistent, reproducible data. Confidently identify viable hits.

Focus your resources

Downstream validation of only confirmed binders reduces hit-to-lead bottlenecks and wasted spend.

*Introductory pricing subject to change. ~$100/rAb includes DNA synthesis, 96-plex binary expression and binding screening, plus SPR on 5 focused binders.

The missing triage step in your workflow

Nuclera adds an essential binding-driven triage gate between AI hit generation and mammalian expression. By using cell-free binary screening to filter out non-binders, you ensure that only the strongest, confirmed candidates reach high-cost biology and downstream characterization.

From AI-generated antibody sequences to data, fast.

Our customer journey is designed to be completely frictionless. You provide the digital sequences, and we handle the wet-lab execution—delivering decision-grade data from 14 business days.

1. You send inputs

Antibody variable region sequences (VH and VL) and biotinylated target antigen(s)**.

2. DNA is prepared

DNA is ordered and prepared for screening

10 business days

antibody-services-table-03-run-the-screen

3. We run the screen

96-plex cell-free IgG1 binary expression and yes/no binding screen.

1 business day

4. Focused SPR

Single-cycle SPR on prioritized binders

2-3 business days

antibody-services-table-05-receive-report

5. You receive the report

A comprehensive data report including yes/no binding screen results and SPR data.

**Nuclera can source and/or biotinylate antigens for a small fee.

Predictive data: Cell‑free antibodies match CHO binding profiles

Nuclera’s engineered cell-free system is optimized for recombinant antibody production, supporting correct protein folding and disulfide bond formation. This ensures that the material screened behaves like the material you will eventually manufacture.

The SPR data below demonstrates that cell-free produced IgG1 antibodies accurately reproduce CHO binding profiles, providing reliable, reproducible data outputs for confident go/no-go decisions. This equivalence supports early triaging, allowing you to confidently confirm binders sooner and cost-effectively.

Figure 1. Single-cycle SPR data for cell-free produced Trastuzumab, Nivolumab, Cetuximab, and Ipilimumab match CHO controls with comparable Kd, kon and koff.

View Validation Poster

A tailored antibody candidate triage service

AI & Protein Design

Validate your models with wet-lab ground truth

Turn AI-generated libraries into experimental data, fast. Our rapid antibody screening service converts large in-silico sets into reproducible binary expression and binding reports, with SPR on prioritized binders. Refine your models, predict binders with higher confidence, and move confirmed binders forward for further validation.

Biopharma

De-risk your pipeline before the expensive steps

Stop burning budget on non-binders. We triage broad panels early, ensuring you only advance top candidates into costly CHO production processes and functional assays. Use our antibody hit validation service to stretch your R&D budget further.

CROs

Reduce FTE and improve project turnaround.

For CROs and platform teams, we provide a repeatable screening layer that helps client programs progress faster. Early library triaging focuses your mammalian capacity on the best candidates—saving FTE time and shortening project turnaround.

Service offering

Choose a standard screening format or build a custom triage pipeline.

Description	Panel size/format	Deliverables	Turnaround
Standard triage service package	94 full-length IgG1 antibodies × 1 antigen	• 96-plex binary expression and yes/no binding screen (94 antibodies + 2 integrated controls). • SPR on 5 confirmed binders included. • PDF report + raw data files	From 14 business days
Additional SPR of confirmed binders	Customer defined	• Full length IgG1 expression and SPR single cycle kinetics • PDF + raw data files	From 2-3 business days

Meet the experts

David Cronk

Head of Alliance Management in BD & Sales

David brings 20 years of CRO experience (Charles River Labs, Domainex) in assay development and high-throughput screening. An expert in in vitro pharmacology, he partners with clients to translate scientific objectives into robust antibody hit-to-lead screening strategies. At Nuclera, David bridges the commercial and technical teams, ensuring every project is scoped to maximize the probability of a successful outcome.

Radha Raman Pandey

Principal Scientist in Protein Science

With over 15 years of research experience, Radha leads the design of Nuclera’s eGene™ assembly technology. His deep expertise in optimizing constructs for mammalian systems is critical to our recombinant antibody expression service, ensuring efficient production of diverse antibody classes. Radha’s work guarantees that the genetic inputs used in our screening workflows are robust, reliable, and optimized for success.

Chris Icke

Senior Scientist Workflow Development in Protein Science

Chris brings over a decade of expertise in protein expression, biochemical characterization, and assay development. He was a key member of the pioneering team that developed Nuclera’s integrated automated workflow for cell-free expression and ranking. Chris ensures our antibody binding screening service delivers consistent, decision-grade data that aligns perfectly with downstream characterization needs.

Give your AI discovery the triage step it’s missing.

Tell us about your library size and screening goals. We’ll map the fastest path to decision-grade data.

Resources & Support

Poster: Cell-Free–Produced Antibodies Match CHO for Binding Assessment

Cell-free protein synthesis (CFPS) offers a simple, rapid and cost-effective way to express and purify antibodies for binding assessment to triage out non-binders before committing to costly biology.

View Poster

Flyer: Nuclera Antibody Services

The missing triage step for AI antibody discovery. Download our flyer to discover how Nuclera filters out non-binders before high-cost downstream validation. Learn how our 96-plex full-length IgG binary cell-free expression and binding screen is combined with focused SPR to help you confidently eliminate bad candidates early. Shrink your list without adding CapEx or headcount,…

View Flyer